CN1217697C - 小带素的肽拮抗剂及其用途 - Google Patents

小带素的肽拮抗剂及其用途 Download PDF

Info

Publication number
CN1217697C
CN1217697C CN998100315A CN99810031A CN1217697C CN 1217697 C CN1217697 C CN 1217697C CN 998100315 A CN998100315 A CN 998100315A CN 99810031 A CN99810031 A CN 99810031A CN 1217697 C CN1217697 C CN 1217697C
Authority
CN
China
Prior art keywords
seq
zonulin
zot
peptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN998100315A
Other languages
English (en)
Chinese (zh)
Other versions
CN1313772A (zh
Inventor
A·法萨诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore filed Critical University of Maryland Baltimore
Publication of CN1313772A publication Critical patent/CN1313772A/zh
Application granted granted Critical
Publication of CN1217697C publication Critical patent/CN1217697C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN998100315A 1998-08-03 1999-07-28 小带素的肽拮抗剂及其用途 Expired - Lifetime CN1217697C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/127,815 1998-08-03
US09/127,815 US6458925B1 (en) 1998-08-03 1998-08-03 Peptide antagonists of zonulin and methods for use of the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100077127A Division CN100348266C (zh) 1998-08-03 1999-07-28 小带素的肽拮抗剂及其用途

Publications (2)

Publication Number Publication Date
CN1313772A CN1313772A (zh) 2001-09-19
CN1217697C true CN1217697C (zh) 2005-09-07

Family

ID=22432094

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100077127A Expired - Lifetime CN100348266C (zh) 1998-08-03 1999-07-28 小带素的肽拮抗剂及其用途
CN998100315A Expired - Lifetime CN1217697C (zh) 1998-08-03 1999-07-28 小带素的肽拮抗剂及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB2005100077127A Expired - Lifetime CN100348266C (zh) 1998-08-03 1999-07-28 小带素的肽拮抗剂及其用途

Country Status (18)

Country Link
US (10) US6458925B1 (enExample)
EP (2) EP1698345B1 (enExample)
JP (1) JP4822585B2 (enExample)
KR (1) KR100610389B1 (enExample)
CN (2) CN100348266C (enExample)
AT (2) ATE329606T1 (enExample)
AU (1) AU745507B2 (enExample)
CA (1) CA2338005C (enExample)
DE (2) DE69942753D1 (enExample)
DK (1) DK1102596T3 (enExample)
ES (1) ES2267282T3 (enExample)
HU (1) HU228079B1 (enExample)
IL (2) IL141082A0 (enExample)
NO (1) NO326552B1 (enExample)
NZ (1) NZ509579A (enExample)
RU (1) RU2214267C2 (enExample)
WO (1) WO2000007609A1 (enExample)
ZA (1) ZA200100829B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
CA2409771C (en) * 2000-05-19 2008-12-02 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
FR2844201A1 (fr) * 2002-09-06 2004-03-12 Rytek Compositions pour le traitement de pathologies fonctionnelles digestives
EP1485074A2 (fr) * 2002-03-15 2004-12-15 Rytek Compositions pour le traitement de pathologies fonctionnelles digestives
KR20080056318A (ko) * 2003-07-15 2008-06-20 유니버시티 오브 메릴랜드, 볼티모어 Ｚｏｔ 및 조눌린에 대한 수용체의 작용제 폴리펩티드
US7125781B2 (en) * 2003-09-04 2006-10-24 Micron Technology, Inc. Methods of forming capacitor devices
US7067385B2 (en) * 2003-09-04 2006-06-27 Micron Technology, Inc. Support for vertically oriented capacitors during the formation of a semiconductor device
US20080038843A1 (en) * 2006-08-11 2008-02-14 University Of Maryland - Baltimore Method of diagnosing celiac disease
US7387939B2 (en) * 2004-07-19 2008-06-17 Micron Technology, Inc. Methods of forming semiconductor structures and capacitor devices
US7439152B2 (en) * 2004-08-27 2008-10-21 Micron Technology, Inc. Methods of forming a plurality of capacitors
US7202127B2 (en) * 2004-08-27 2007-04-10 Micron Technology, Inc. Methods of forming a plurality of capacitors
US20060046055A1 (en) 2004-08-30 2006-03-02 Nan Ya Plastics Corporation Superfine fiber containing grey dope dyed component and the fabric made of the same
US7547945B2 (en) 2004-09-01 2009-06-16 Micron Technology, Inc. Transistor devices, transistor structures and semiconductor constructions
US7320911B2 (en) * 2004-12-06 2008-01-22 Micron Technology, Inc. Methods of forming pluralities of capacitors
FR2879100B1 (fr) 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
US7557015B2 (en) * 2005-03-18 2009-07-07 Micron Technology, Inc. Methods of forming pluralities of capacitors
GB2425654B (en) * 2005-04-29 2010-03-17 Seiko Epson Corp A method of fabricating a heterojunction of organic semiconducting polymers
EP1722466A1 (en) * 2005-05-13 2006-11-15 STMicroelectronics S.r.l. Method and relative circuit for generating a control voltage of a synchronous rectifier
US7544563B2 (en) 2005-05-18 2009-06-09 Micron Technology, Inc. Methods of forming a plurality of capacitors
US7517753B2 (en) * 2005-05-18 2009-04-14 Micron Technology, Inc. Methods of forming pluralities of capacitors
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
US7282401B2 (en) 2005-07-08 2007-10-16 Micron Technology, Inc. Method and apparatus for a self-aligned recessed access device (RAD) transistor gate
US7199005B2 (en) * 2005-08-02 2007-04-03 Micron Technology, Inc. Methods of forming pluralities of capacitors
US7867851B2 (en) 2005-08-30 2011-01-11 Micron Technology, Inc. Methods of forming field effect transistors on substrates
US7700441B2 (en) 2006-02-02 2010-04-20 Micron Technology, Inc. Methods of forming field effect transistors, methods of forming field effect transistor gates, methods of forming integrated circuitry comprising a transistor gate array and circuitry peripheral to the gate array, and methods of forming integrated circuitry comprising a transistor gate array including first gates and second grounded isolation gates
DK2777695T3 (en) 2006-02-09 2018-12-17 Alba Therapeutics Corp Formulations for a tight-junction effector
US7557013B2 (en) 2006-04-10 2009-07-07 Micron Technology, Inc. Methods of forming a plurality of capacitors
US7602001B2 (en) * 2006-07-17 2009-10-13 Micron Technology, Inc. Capacitorless one transistor DRAM cell, integrated circuitry comprising an array of capacitorless one transistor DRAM cells, and method of forming lines of capacitorless one transistor DRAM cells
US7772632B2 (en) 2006-08-21 2010-08-10 Micron Technology, Inc. Memory arrays and methods of fabricating memory arrays
US7589995B2 (en) 2006-09-07 2009-09-15 Micron Technology, Inc. One-transistor memory cell with bias gate
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US7902081B2 (en) 2006-10-11 2011-03-08 Micron Technology, Inc. Methods of etching polysilicon and methods of forming pluralities of capacitors
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
WO2008073627A2 (en) 2006-11-03 2008-06-19 Alba Therapeutics Corporation Method of diagnosing and treating asthma
US7785962B2 (en) 2007-02-26 2010-08-31 Micron Technology, Inc. Methods of forming a plurality of capacitors
WO2009023311A2 (en) * 2007-05-07 2009-02-19 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2008150981A2 (en) * 2007-05-30 2008-12-11 Alba Therapeutics Corporation Novel short peptides that inhibit the opening of mammalian tight junctions
US7923373B2 (en) 2007-06-04 2011-04-12 Micron Technology, Inc. Pitch multiplication using self-assembling materials
WO2008154493A2 (en) * 2007-06-07 2008-12-18 Alba Therapeutics Corporation Novel peptides that inhibit the opening of mammalian tight junctions
WO2008154350A2 (en) * 2007-06-08 2008-12-18 Alba Therapeutics Corporation Use of tight junction agonists to suppress immune responses
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) * 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
US7682924B2 (en) 2007-08-13 2010-03-23 Micron Technology, Inc. Methods of forming a plurality of capacitors
US8785374B2 (en) * 2007-10-19 2014-07-22 Alba Therapeutics Corporation Inhibitors of mammalian tight junction opening
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
WO2009110947A2 (en) * 2007-12-19 2009-09-11 Alba Therapeutics Corporation Compositions and methods for inhibiting cytokine production
US8388851B2 (en) 2008-01-08 2013-03-05 Micron Technology, Inc. Capacitor forming methods
US8274777B2 (en) 2008-04-08 2012-09-25 Micron Technology, Inc. High aspect ratio openings
WO2009137572A2 (en) 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
US7759193B2 (en) 2008-07-09 2010-07-20 Micron Technology, Inc. Methods of forming a plurality of capacitors
CN104940927A (zh) * 2009-06-10 2015-09-30 马里兰巴尔的摩大学 表皮生长因子受体(egfr)与蛋白酶活化受体2(par2)对肠道通透性的调节
RU2410765C1 (ru) * 2009-07-21 2011-01-27 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ профилактики токсического действия никеля у экспериментальных животных при хроническом отравлении
RU2412489C1 (ru) * 2009-09-01 2011-02-20 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ профилактики хронической токсической кардиопатии у экспериментальных животных
US8518788B2 (en) 2010-08-11 2013-08-27 Micron Technology, Inc. Methods of forming a plurality of capacitors
US9076680B2 (en) 2011-10-18 2015-07-07 Micron Technology, Inc. Integrated circuitry, methods of forming capacitors, and methods of forming integrated circuitry comprising an array of capacitors and circuitry peripheral to the array
US8946043B2 (en) 2011-12-21 2015-02-03 Micron Technology, Inc. Methods of forming capacitors
KR102236462B1 (ko) 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
US8652926B1 (en) 2012-07-26 2014-02-18 Micron Technology, Inc. Methods of forming capacitors
EP3896082A1 (en) * 2013-11-05 2021-10-20 Bio-Rad Laboratories, Inc. Pre-haptoglobin-2 monoclonal antibodies and uses thereof
WO2015154010A1 (en) * 2014-04-04 2015-10-08 Perrow Wendy Methods of treating celiac disease with larazotide
WO2018148654A1 (en) 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing environmental enteropathy
US11608359B2 (en) 2018-02-23 2023-03-21 9 Meters Biopharma, Inc. Compounds and methods for treating tight junction permeabtility
CN117597137A (zh) 2021-04-19 2024-02-23 伊布里斯有限责任公司 用于治疗儿童（mis-c）和成人（mis-a）多系统炎症综合征的连蛋白拮抗剂
CN118873629B (zh) * 2024-09-27 2024-12-10 北京大学口腔医学院 醋酸拉唑肽在制备促进成骨药物中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US667048A (en) * 1900-07-06 1901-01-29 Edson F Whitman Torpedo-projectile.
US2419898A (en) 1943-12-10 1947-04-29 Int Harvester Co Shelled corn saver for husking devices
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
WO1994011505A1 (en) * 1992-11-10 1994-05-26 Washington University Pars planitis specific polypeptides
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
EP0674710B1 (en) * 1992-11-16 2003-05-02 Cancer Research Fund Of Contra Costa Peptides with broad neoplastic specificity
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
CO4600637A1 (es) * 1996-03-15 1998-05-08 Corixa Corp Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
US5912323A (en) * 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6506577B1 (en) * 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
NZ510150A (en) * 1998-09-14 2002-10-25 Univ Maryland Method of using zot or zonulin to inhibit lymphocyte proliferation in an antigen-specific manner
CA2409771C (en) * 2000-05-19 2008-12-02 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
US7531504B2 (en) 2009-05-12
DE69942753D1 (de) 2010-10-21
EP1102596A4 (en) 2002-08-14
US20050209161A1 (en) 2005-09-22
US20110183923A1 (en) 2011-07-28
US6670448B2 (en) 2003-12-30
US7189696B2 (en) 2007-03-13
IL141082A (en) 2012-09-24
HK1082210A1 (zh) 2006-06-02
EP1698345A2 (en) 2006-09-06
ES2267282T3 (es) 2007-03-01
HUP0103321A3 (en) 2006-01-30
AU5459099A (en) 2000-02-28
CA2338005C (en) 2012-05-29
CN100348266C (zh) 2007-11-14
EP1102596B1 (en) 2006-06-14
JP4822585B2 (ja) 2011-11-24
IL141082A0 (en) 2002-02-10
RU2214267C2 (ru) 2003-10-20
WO2000007609A1 (en) 2000-02-17
KR100610389B1 (ko) 2006-08-09
KR20010072245A (ko) 2001-07-31
AU745507B2 (en) 2002-03-21
US20040082512A1 (en) 2004-04-29
EP1102596A1 (en) 2001-05-30
HUP0103321A2 (hu) 2001-12-28
US6936689B2 (en) 2005-08-30
US20140128328A1 (en) 2014-05-08
ATE329606T1 (de) 2006-07-15
CN1679915A (zh) 2005-10-12
US20060276399A1 (en) 2006-12-07
US20130190247A1 (en) 2013-07-25
DK1102596T3 (da) 2006-10-09
US20020115825A1 (en) 2002-08-22
NO20010567L (no) 2001-04-02
NO20010567D0 (no) 2001-02-02
EP1698345A3 (en) 2006-09-13
US20090082279A1 (en) 2009-03-26
JP2002524393A (ja) 2002-08-06
US6458925B1 (en) 2002-10-01
ATE480252T1 (de) 2010-09-15
HU228079B1 (en) 2012-10-29
EP1698345B1 (en) 2010-09-08
CN1313772A (zh) 2001-09-19
NO326552B1 (no) 2009-01-05
DE69931929T2 (de) 2007-02-08
US7582603B2 (en) 2009-09-01
US20080051349A1 (en) 2008-02-28
CA2338005A1 (en) 2000-02-17
ZA200100829B (en) 2002-06-26
NZ509579A (en) 2003-07-25
DE69931929D1 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
CN1217697C (zh) 小带素的肽拮抗剂及其用途
CN1034080C (zh) 胰岛素类似物的制备方法
CN1178955C (zh) 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
CN1262688A (zh) 整合蛋白结合肽及其应用
CN1942583A (zh) Hpv58l1在酵母中的最优化表达
CN1675362A (zh) Hla－a24限制性癌抗原肽
CN1649895A (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
CN101080239A (zh) 作为慢性肝炎治疗性疫苗的稳定化HBc嵌合体颗粒
CN1703424A (zh) Glp－1衍生物及其经粘膜吸收的制剂
CN1839149A (zh) 能够结合转化生长因子β1(TGF－β1)的肽
CN1136778A (zh) 与一种精子区带结合蛋白的自身抗原性抗原决定基相对应的精子抗原
CN101068832A (zh) 包含唯bh3域蛋白中bh3结构域的融合蛋白
CN1226897A (zh) 来自mage－2的分离的肽
CN1315963A (zh) 结合膜联蛋白的苯并二氮杂䓬类和苯并硫杂吖庚因衍生物和hbsag肽,其组合物和用途
CN1950106A (zh) 用作肿瘤特异性疫苗的合成蛋白质
CN1838967A (zh) 稳定的免疫原性HBc嵌合体颗粒
CN1110503C (zh) 编码gage肿瘤排斥抗原的分离的截短的核酸分子
CN1243018C (zh) 一种新的血管发生抑制剂
CN1886148A (zh) 被设计用于破坏NEMO寡聚化的肽对NF－κB活化的选择性抑制
CN1852919A (zh) Zot和连蛋白受体的激动剂多肽
CN1264980C (zh) 新型肿瘤抗原蛋白sart－3及其肿瘤抗原肽
CN1656116A (zh) 包含hpv－16病毒的突变e7蛋白的非免疫抑制免疫原性组合物或疫苗组合物
CN1495262A (zh) gp350/220的非剪接变异体
CN1190437A (zh) 骨刺激因子
CN1191089C (zh) 与ELAGIGILTV肽相结合的肠细菌OmpA蛋白用于治疗黑素瘤的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20050907

CX01 Expiry of patent term